Latest Health News

Tasmea Limited has announced the acquisition of WorkPac Group for up to A$60.7 million, significantly enhancing its workforce solutions capabilities and positioning the company for growth amid Australia's skilled labour shortages.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

LGI Limited reported robust FY25 results with a 14% rise in EBITDA and secured six new contracts, positioning the company for a 25-30% EBITDA increase in FY26. Key project completions and expansions underpin this momentum.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

OMG Group has inked a five-year exclusive distribution agreement with SANDAI, a premium Japanese matcha producer, positioning itself to capture significant growth in Australia’s expanding matcha market.

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.

Nufarm reported a mixed FY25 with strong crop protection profits offset by a statutory loss from seed restructuring, while targeting earnings growth and debt reduction in FY26.

Judo Capital Holdings Limited announces a fully franked quarterly distribution of AUD 1.79129 per Capital Note, reflecting a 7.1% annualised yield based on current market rates.

Sandon Capital Investments Limited has announced fully franked monthly dividends for the first quarter of 2026, offering investors an attractive annualised yield of 6.0%. The company’s strong profit reserves underpin its capacity to sustain dividend payments over the coming years.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.